Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond

metastasis
oophorectomy
plain x-ray
blood transfusion
cancer
  • 116 views
  • 13 May, 2022
  • 1 location
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)

This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with

  • 31 views
  • 12 Mar, 2022
  • 18 locations
Tremelimumab, Durvalumab, and Belinostat for the Treatment of ARID1A Mutated Metastatic or Unresectable, Locally Advanced Urothelial Carcinoma (RESOLVE)

This phase I trial studies the side effects and best dose of belinostat when given together with tremelimumab and durvalumab in treating patients with urothelial cancer that has spread to other

  • 0 views
  • 25 May, 2022
  • 1 location
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

The purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel, following initial chemotherapy with FOLFOX. The investigators want to find out what effects, good and/or bad, this combination has on the patient …

esophagectomy
oophorectomy
chemoradiotherapy
carboplatin
medi4736
  • 52 views
  • 04 Jun, 2022
  • 7 locations
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma

This study is a Phase Ib/II, multi-center, open-label study of tebentafusp (IMCgp100) as a single agent and in combination with durvalumab (MEDI4736) and/or tremelimumab in metastatic cutaneous

advanced melanoma
pd-1 inhibitor
BRAF
targeted therapy
cytotoxic t-lymphocyte antigen 4
  • 2 views
  • 10 Jul, 2022
  • 4 locations
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Background Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months. Researchers are evaluating a combination of treatment drugs to delay the progression of HCC; aiming to help people with HCC live longer. Objective To …

EGFR
neutrophil count
pet scan
cancer
TACE
  • 0 views
  • 24 Jul, 2022
  • 1 location
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer

We will conduct a Phase I trial testing whether local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab in localized bladder

carcinoma
bladder tumor
hormone therapy
durvalumab
invasive bladder cancer
  • 0 views
  • 25 Nov, 2021
  • 1 location
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.

measurable disease
TACE
chemoembolization
durvalumab
ascites
  • 5 views
  • 17 Mar, 2022
  • 1 location
Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition

This phase II trial studies how well standard of care hypofractionated radiation therapy followed by durvalumab with or without tremelimumab works in treating patients with hepatocellular cancer

  • 0 views
  • 25 Apr, 2022
  • 1 location
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with

  • 8 views
  • 08 Jul, 2022
  • 11 locations